cancer%20pain
CANCER PAIN
Cancer pain is an unpleasant sensory & emotional experience due to actual or potential tissue damage in patients with cancer.
Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival.
Pancreatic, head & neck cancer has a high prevalence of cancer pain.
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they will be screened & evaluated for pain.
Drug Information

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Management of chronic pain & intractable pain in patients requiring continuous opioid administration for a...

Indication: Adjunctive therapy in treatment of partial seizures w/ & w/o secondary generalization in adults & chil...

Indication: Moderate to severe pain.

Indication: Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain.

Indication: Severe acute & chronic pain. Painful diagnostic or therapeutic measures.

Indication: Moderate to severe acute & chronic pain & in painful diagnostic measure & surgery.

Indication: Relief of fever & mild to moderate pain including headache, dental pain, post-op pain, dysmenorrhoea; musc...

Indication: Major depressive disorder, generalized anxiety disorder. Management of diabetic peripheral neuropathic pain.

Indication: Depression, including depression associated w/ anxiety, generalized anxiety disorders (GAD) including long-ter...

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 07 May 2019

Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.

Roshini Claire Anthony, 13 May 2019

Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.